Company intelligence / Profile preview

FX Therapeutics

Lexington, Massachusetts, United Statesca.linkedin.com ↗

Ownership: Private
Employees: ~51-200
Development stage: Preclinical

Overview

Frequency Therapeutics' lead candidate FX-322 for sensorineural hearing loss failed its Phase 2b study in February 2023, showing no significant improvement in speech perception compared to placebo. The company has discontinued its hearing loss programs (FX-322 and FX-345) and is now focusing on its remyelination program for multiple sclerosis, which is in pre-clinical stage.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Partnerships

Astellas Pharma Inc.Eleven Therapeutics

Beyond the preview

Go deeper on FX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX Therapeutics.

Explore the full profile